A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer

Clinical trial NCT02685306 · WITHDRAWN

Trial details

NCT number: NCT02685306
Sponsor: Peregrine Pharmaceuticals
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Triple Negative Breast Neoplasms Triple-Negative Breast Neoplasm Triple-Negative Breast Cancer Triple Negative Breast Cancer ER-Negative PR-Negative HER2-Negative Breast Neoplasms ER-Negative PR-Negative HER2-Negative Breast Cancer

Start date: 2016-03-01
Primary completion: 2017-04-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.